Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Endpoint summary

Currently viewing:

Administrative data

Key value for chemical safety assessment

Effects on fertility

Description of key information

The NOAEL of Everzol SB26 in rat’s reproductive performance was 1000 mg/kg/day (OECD TG421).

Link to relevant study records
Reference
Endpoint:
screening for reproductive / developmental toxicity
Type of information:
experimental study
Adequacy of study:
key study
Study period:
28 day dosing males, typical 55 days dosing females.
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Justification for type of information:
Good 2016 study which includes observation of colour changes in organs and GI tract.
Qualifier:
according to guideline
Guideline:
OECD Guideline 421 (Reproduction / Developmental Toxicity Screening Test)
GLP compliance:
yes
Specific details on test material used for the study:
Purity ca 78%
Results expressed as whole test material and not adjusted for purity.
Species:
rat
Strain:
other: Crl:CD(SD)
Sex:
male/female
Details on test animals or test system and environmental conditions:
- Source: BioLASCO Taiwan Co., Ltd., Taipei, Taiwan
- Age at study initiation: about 9-week old
- Weight at study initiation: Males: 311-379 g; Females: 199-240 g
- Housing: Except for the mating period, animals were housed individually in polycarbonate cages. While mating, animals were pair-housed in stainless steel wire mesh cages.
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 11 days
- Temperature (°C): 21 ± 2 °C
- Humidity (%): 50 ± 20%
- Photoperiod: 12-hrs dark / 12-hrs light
Route of administration:
oral: gavage
Vehicle:
water
Remarks:
water for injection (WFI)
Details on exposure:
Animals were dosed for the following periods:
All rats 14 day pre-maitng
All rats14 day mating period, with males terminated after this period
Females doed for duration of gestation (typically 23 days) and until 4 days after birth.
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
Homogeneity and concentration confirmation using HPLC-UV methods
Samples collected from middle of control, low, mid and high dose samples
Duration of treatment / exposure:
28 day dosing males, typical 55 days dosing females.
Frequency of treatment:
Daily gavage
Dose / conc.:
0 mg/kg bw/day (nominal)
Remarks:
Dose group 1
Dose / conc.:
100 mg/kg bw/day (nominal)
Remarks:
Dose group 2
Dose / conc.:
300 mg/kg bw/day (nominal)
Remarks:
Dose group 3
Dose / conc.:
1 000 mg/kg bw/day (nominal)
Remarks:
Dose group 4
No. of animals per sex per dose:
Male: ten
Female: ten
Control animals:
yes, concurrent vehicle
Parental animals: Observations and examinations:
Clinical observations twice daily
Weighings made weekly with food consumption measured
Litter observations:
Litters observed as as possible after delivery for gross abnormalities
Live pups were counted, sexed and weighed.
Postmortem examinations (parental animals):
Males were terminated on Day 29; females typically after 55 days
Number of implantation sites were examined in females
Full necropsy performed.
Postmortem examinations (offspring):
Gross examinations were performed
Clinical signs:
effects observed, treatment-related
Description (incidence and severity):
Overall, no death was observed in males and females during the study period. The test article-related clinical observations were blue colored/soft feces, blue/blue-green colored urine, blue coloured body skin and blue-purple hair stain on the back in males and/or females.
Mortality:
no mortality observed
Body weight and weight changes:
no effects observed
Urinalysis findings:
effects observed, treatment-related
Description (incidence and severity):
Blue colour of urine
Reproductive performance:
no effects observed
Dose descriptor:
NOAEL
Effect level:
1 000 mg/kg bw/day
Based on:
test mat.
Sex:
male/female
Basis for effect level:
clinical signs
mortality
Critical effects observed:
no
Clinical signs:
no effects observed
Mortality / viability:
no mortality observed
Dose descriptor:
NOAEL
Generation:
F1
Effect level:
> 1 000 mg/kg bw/day (nominal)
Based on:
test mat.
Remarks on result:
not measured/tested
Reproductive effects observed:
no

Dose Formulation Analysis

On the first and last preparation, the difference between the mean value and the targeted concentration for all dose group formulations were within ± 15.0%. The homogeneity verification revealed that the precision of samples for the low and high dose formulation were ≤ 10.0%.

 

Mortality and Clinical Observations

All animals survived the study period. Bluepurple colored body skin was observed in high dose females since the day of the 36th dosing to the end of study. Blue-purple stained hair on the back was observed in one high dose male (ID# 1037) and in one high dose female (ID# 0039) animals.

 

Body Weights

In males, statistically significantly increased body weight gain compared to the controls was observed in males of Group 3 on D15. There were no statistically significant differences in body weight and body weight gain changes in treated groups compared to control animals in females.

 

Food Consumption

There was no statistically significant difference between treated and control groups in both genders.

 

Cohabitation and Pregnancy

In males, a positive indication of mating was obtained for 9, 10, 10 and 9 of 10 in Groups 1 to 4 animals, resulting in a mating index of 90%, 100%, 100% and 90%, respectively. In females, a positive indication of mating was obtained for 10 of 10 in Group 2 to 4 animals and for 9 of 10 in Group 1 animals. The mating index was 90%, 100%, 100% and 100% for Group 1 to 4, respectively. There was only one animal in Group 4 that showed a pre-coital interval over 5 days. In this female, the mating with the first male failed but the copulation with another male was successful. In Group 2, 3 animals with positive indications of mating were later found not to be pregnant. In Group 4, one animal with positive indications of mating was later found not to be pregnant. All Groups 1 and 3 animals were found to be pregnant. Thus, the fertility index was 100%, 70%, 100% and 90% in the control, low, mid and high dose group, respectively. The average length of gestation was 22.1 or 22.2 days without dosedependency.

 

Litter Observation

All pregnant rats delivered live pups. The gestation index was 100% in all groups. One dead pup was observed at birth in Groups 2 and 4. The incidence of the dams with dead pups at birth was 0%, 14%, 0% and 11% in Group 1, 2, 3 and 4, respectively. On P4, all pups survived so that the 4-day survival index was 100.0% in all groups. No external abnormal pups were observed at birth in the control and treated groups. At birth, 48.5% to 51.4% of pups were male and on P4, 49.2% to 54.7% pups were male. The gender difference at birth and on P4 was a consequence of a difficult sex determination at birth. The litter weights in all groups were increased from P0 to P4.

 

Male Gross Examination, Organ Weight and Histopathology

There were no statistically significant differences in testis and epididymis weightsbetween control and treated groups. Decreased size of testes was observed in one Group 2 (ID# 1011).

 

Females Gross, Uterus Examination and Histopathology

There were no statistically significant differences on number of corpora lutea and implantation between control and treated groups. Treatment-related gross findings included discoloration of the intestine, kidney, lung, mesenteric lymph node, and uterus. Discoloration of the lung was correlated with foamy alveolar macrophages with intracytoplasmic blue pigment in two Group 4 females ((IDs# 0036 and 0040) microscopically.

Conclusions:
According to OECD 421 test method, the no observed adverse effect level of Reactive Blue 187 in rat’s reproductive performance was 1000 mg/kg/day.
Executive summary:

This test using the procedures outlined in the QPS Study Plan for T65315035-RP and OECD 421. Reactive Blue 187 (100, 300 or 1000 mg/kg/day) was given orally by gavage once daily to male rats for 28 days and female rats for 40 to 53 days, depending on the time of copulation and gestation. Dose-related clinical observations in the treated groups included blue colored/soft feces, blue/blue-green colored urine, blue colored body skin and blue-purple hair stain on the back. Test article-related macro- or microscopic changes were discoloration in intestine, kidney, lung, mesenteric lymph node and uterus, and foamy alveolar macrophages, with intracytoplasmic blue pigment in the lung. However, there were no test article-related effects on male and female rat's reproductive performance such as gonadal function, mating behavior, conception, development of the conceptus and parturition.

The no observed adverse effect level in rat's reproductive performance was 1000 mg/kg/day.

Effect on fertility: via oral route
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
NOAEL
1 000 mg/kg bw/day
Study duration:
subacute
Species:
rat
Effect on fertility: via inhalation route
Endpoint conclusion:
no study available
Effect on fertility: via dermal route
Endpoint conclusion:
no study available
Additional information

Effect on fertility: via oral route

Everzol SB26 (100, 300 or 1000 mg/kg/day) was given orally by gavage once daily to male rats for 28 days and female rats for 40 to 53 days, depending on the time of copulation and gestation. Dose-related clinical observations in the treated groups included blue colored/soft feces, blue/blue-green colored urine, blue colored body skin and blue-purple hair stain on the back. Test article-related macro- or microscopic changes were discoloration in intestine, kidney, lung, mesenteric lymph node and uterus, and foamy alveolar macrophages, with intracytoplasmic blue pigment in the lung. However, there were no test article-related effects on male and female rats’ reproductive performance such as gonadal function, mating behavior, conception, development of the conceptus and parturition. The no observed adverse effect level of Everzol SB26 in rat’s reproductive performance was 1000 mg/kg/day.

Effects on developmental toxicity

Effect on developmental toxicity: via oral route
Endpoint conclusion:
no study available
Effect on developmental toxicity: via inhalation route
Endpoint conclusion:
no study available
Effect on developmental toxicity: via dermal route
Endpoint conclusion:
no study available

Justification for classification or non-classification

Additional information